Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 2/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27807019 | 0.88 | SSTR4 (0.42) | SSTR4MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL12415575 | 0.87 | KDM4E (0.55) | KMT2AALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL3512971 | 0.81 | HTR6 (0.47) | ALDH1A1KDM4EMAPTMAPK1HTT | |
| SCHEMBL3642902 | 0.81 | GAA (0.50) | SSTR4ALDH1A1KDM4EHPGDSCN1A | |
| SCHEMBL10371031 | 0.81 | CDK1 (0.43) | SSTR4KDM4ESCN1ASCN2ASCN3A | |
| SCHEMBL6886552 | 0.81 | HTR3A (0.55) | ADRA1AADRA1BMEN1KMT2AL3MBTL1 | |
| SCHEMBL22605677 | 0.80 | JAK2 (0.50) | ALDH1A1KDM4ECDK1NSD2 | |
| SCHEMBL3512534 | 0.78 | INSR (0.43) | MEN1KMT2AALDH1A1MAPTMAPK1 | |
| SCHEMBL14525000 | 0.78 | ALDH1A1 (0.57) | MEN1KMT2AALDH1A1KDM4ENPC1 | |
| SCHEMBL9855953 | 0.77 | CDK1 (0.41) | SSTR4KMT2ASCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144813-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-05-12 | — | — | US | disclosed |
| US-20200377487-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-12-03 | — | — | US | disclosed |
| US-20190241546-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-08-08 | — | — | US | disclosed |
| US-10081622-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-09-25 | — | — | US | disclosed |
| US-20170158677-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-08 | — | — | US | disclosed |
| US-9616059-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-04-11 | — | — | US | disclosed |
| EP-2176231-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-10-19 | — | — | EP | disclosed |
| US-20160095856-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-04-07 | — | — | US | disclosed |
| US-9255087-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-02-09 | — | — | US | disclosed |
| US-9102662-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-11 | — | — | US | disclosed |
| US-9085558-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-07-21 | — | — | US | disclosed |
| US-9029356-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-05-12 | — | — | US | disclosed |
| US-20150065520-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-05 | — | — | US | disclosed |
| US-20150057291-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-26 | — | — | US | disclosed |
| US-20150057292-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-26 | — | — | US | disclosed |
| US-20140228351-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-14 | — | — | US | disclosed |
| US-8673893-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-03-18 | — | — | US | disclosed |
| US-20130018036-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-17 | — | — | US | disclosed |
| US-8299057-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-30 | — | — | US | disclosed |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081622-B2 | Substituted indazole derivatives active as kinase inhibitors | MAP3K19, ABL1, MAP3K20 | ADRA1A 3486/4885ADRA1B 3253/4885SSTR4 4082/4885 |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | ADRA1A 2651/4885ADRA1B 2349/4885SSTR4 4172/4885 |
| US-20160095856-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | ADRA1A 3486/4885ADRA1B 3253/4885SSTR4 4082/4885 |
| US-20200377487-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | ADRA1A 3486/4885ADRA1B 3253/4885SSTR4 4082/4885 |
| US-20190241546-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | ADRA1A 3486/4885ADRA1B 3253/4885SSTR4 4082/4885 |
| US-20130018036-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | ADRA1A 2651/4885ADRA1B 2349/4885SSTR4 4172/4885 |
| US-20150065520-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | ADRA1A 3486/4885ADRA1B 3253/4885SSTR4 4082/4885 |
| US-20220144813-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | ADRA1A 3486/4885ADRA1B 3253/4885SSTR4 4082/4885 |
| US-20150057292-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | ADRA1A 3486/4885ADRA1B 3253/4885SSTR4 4082/4885 |
| US-20140228351-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | ADRA1A 3486/4885ADRA1B 3253/4885SSTR4 4082/4885 |
| US-20150057291-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | ADRA1A 3486/4885ADRA1B 3253/4885SSTR4 4082/4885 |
| US-20170158677-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | ADRA1A 3486/4885ADRA1B 3253/4885SSTR4 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.